ATE47155T1 - Monoklonaler antikoerper. - Google Patents

Monoklonaler antikoerper.

Info

Publication number
ATE47155T1
ATE47155T1 AT83303547T AT83303547T ATE47155T1 AT E47155 T1 ATE47155 T1 AT E47155T1 AT 83303547 T AT83303547 T AT 83303547T AT 83303547 T AT83303547 T AT 83303547T AT E47155 T1 ATE47155 T1 AT E47155T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
human
mature
cells
monoclonal antibody
Prior art date
Application number
AT83303547T
Other languages
English (en)
Inventor
Ellis L Reinherz
Stuart F Schlossman
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23542917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE47155(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE47155T1 publication Critical patent/ATE47155T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT83303547T 1982-06-21 1983-06-20 Monoklonaler antikoerper. ATE47155T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/390,548 US4443427A (en) 1982-06-21 1982-06-21 Monoclonal antibody
EP83303547A EP0097518B1 (de) 1982-06-21 1983-06-20 Monoklonaler Antikörper

Publications (1)

Publication Number Publication Date
ATE47155T1 true ATE47155T1 (de) 1989-10-15

Family

ID=23542917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT83303547T ATE47155T1 (de) 1982-06-21 1983-06-20 Monoklonaler antikoerper.

Country Status (6)

Country Link
US (1) US4443427A (de)
EP (1) EP0097518B1 (de)
JP (1) JPS5959630A (de)
AT (1) ATE47155T1 (de)
CA (1) CA1206898A (de)
DE (1) DE3380697D1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247538A (en) * 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
US4618577A (en) * 1983-02-09 1986-10-21 The Regents Of The University Of California Human-human hybridoma, CLNH5
US4678747A (en) * 1983-02-18 1987-07-07 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies for detection of an H (O) blood group antigen
US4677056A (en) * 1983-08-18 1987-06-30 Sloan-Kettering Institute For Cancer Research Monoclonal antibody subsetting human helper and killer T-cells and method
USRE35277E (en) * 1983-09-11 1996-06-18 Yeda Research And Development Co. Ltd. Cell membrane proteins, compositions containing them and procedure for their preparation
IL69686A (en) * 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
US4645738A (en) * 1983-09-30 1987-02-24 Memorial Sloan-Kettering Institute Cancer Center Method for differential diagnosis of T cell leukemias using monoclonal antibodies
JPS60231699A (ja) * 1983-11-09 1985-11-18 Aichiken 正常及び悪性ヒト造血器細胞に対するモノクローナル抗体
US4722903A (en) * 1983-11-14 1988-02-02 New York Blood Center, Inc. Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fiberin I or human fibrin II
US4851334A (en) * 1984-01-03 1989-07-25 The New York Blood Center, Inc. Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fibrin I or human fibrin II
US5130144B1 (en) * 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4965204A (en) * 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US4886745A (en) * 1984-03-30 1989-12-12 Syntex Inc. Monoclonal antibody specific for human basal cell surface antigen
US4782015A (en) * 1984-03-30 1988-11-01 Syntex (U.S.A.) Inc. Method for determining the presence of malignant cells
DE3574710D1 (de) * 1984-04-13 1990-01-18 Litton Bionetics Inc Leukoregulin, ein antitumor-lymphokin und dessen verwendung als heilmittel.
US4695538A (en) * 1984-06-01 1987-09-22 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cell surface antigens
US4708930A (en) * 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
US4735210A (en) * 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5011684A (en) * 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5336489A (en) * 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
GB8525974D0 (en) * 1985-10-22 1985-11-27 Nyegaard & Co As Chemical substance
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
IL82841A (en) * 1986-06-13 1992-11-15 Oncogen Ligands and in vitro methods for augmenting b-cell proliferation
US5665216A (en) * 1986-10-21 1997-09-09 Northeastern University Capillary column for high performance electrophoretic separation and detection of SDS proteins and system and using the same
US4997537A (en) * 1986-10-21 1991-03-05 Northeastern University High performance microcapillary gel electrophoresis
US4877599A (en) * 1986-11-10 1989-10-31 New England Deaconess Hospital Corporation Detection of vascular disease with labelled antibodies
US4810632A (en) * 1986-12-01 1989-03-07 Scripps Clinic And Research Foundation Cell surface antigen detection method
US5176998A (en) * 1986-12-01 1993-01-05 The Scripps Research Institute Cell surface antigen detection method
US5762933A (en) * 1987-01-05 1998-06-09 Institut National De La Sante Et De La Recherche Medicale Method for preventing and treating graft failure in a human patient using a monoclonal antibody specific for leucocyte functional antigen LFA-1
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
DE3855236D1 (de) * 1987-08-17 1996-05-30 Us Commerce Verfahren zur behandlung der bösartigen und autoimmunen krankheiten beim menschen
US5002869A (en) * 1987-11-02 1991-03-26 Dana-Farber Cancer Institute Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes
US5824311A (en) * 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
GB8728854D0 (en) * 1987-12-10 1988-01-27 British Telecomm Optical device
DE3888138T2 (de) * 1987-12-23 1994-08-04 Becton Dickinson Co Monoklonaler Antikörper fähig zum Unterdrücken der Proliferation von T-Lymphozyten.
FI891226L (fi) * 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
JPH0210157A (ja) * 1988-06-28 1990-01-12 Shin Etsu Chem Co Ltd ヒトｔ細胞の分化成熟度検査薬
JPH0210158A (ja) * 1988-06-28 1990-01-12 Shin Etsu Chem Co Ltd 血清用ダウン症診断薬
US5391481A (en) * 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
FR2676069B1 (fr) * 1991-05-02 1994-09-09 Imnunotech Nouvelles molecules de adn recombinants contenant la partie codante d'une chaine vbeta2 du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant.
CA2137561C (en) 1992-07-06 2001-10-23 Thomas R. Sykes Photoactivation of proteins for conjugation purposes
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AU2002243905B2 (en) * 2001-01-26 2007-11-08 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4363799A (en) * 1979-03-20 1982-12-14 Ortho Pharmaceutical Corporation Monoclonal antibody to human T cells, and methods for preparing same
US4381295A (en) * 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
US4361549A (en) * 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
ZA805743B (en) * 1979-09-18 1982-04-28 Ortho Pharma Corp Hybrid cell line for producing monoclonal antibody to human cytotoxic and supressor t cells, antibody, and methods
US4364932A (en) * 1979-09-18 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to human cytotoxic and suppressor T cells and methods of preparing same
US4361550A (en) * 1979-12-04 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human suppressor T cells and methods of preparing same
US4364933A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human thymocyte antigen and methods of preparing same
US4364935A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human prothymocyte antigen and methods of preparing same
US4364937A (en) * 1980-01-08 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human T cell antigen and methods of preparing same
US4364936A (en) * 1980-01-08 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human monocyte antigen and methods of preparing same
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
JPS56143955A (en) * 1980-04-10 1981-11-10 Fujirebio Inc Method for diagnosis of initial infection of syphilis
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies

Also Published As

Publication number Publication date
US4443427A (en) 1984-04-17
JPH0231957B2 (de) 1990-07-17
CA1206898A (en) 1986-07-02
EP0097518B1 (de) 1989-10-11
DE3380697D1 (en) 1989-11-16
EP0097518A3 (en) 1985-10-09
EP0097518A2 (de) 1984-01-04
JPS5959630A (ja) 1984-04-05

Similar Documents

Publication Publication Date Title
ATE47155T1 (de) Monoklonaler antikoerper.
ES486263A0 (es) Un procedimiento para purificar proteinas con pesos moleculares superiores a 12.000,en particular interferon
DE122006000007I1 (de) Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden.
EP0117114A3 (en) Method and device for bacterial testing
DE69534235D1 (de) Cytokin lerk-7
NL300372I1 (nl) Hybride immunoglobulinen voor gebruik bij therapeutische werkwijzen
MY106592A (en) Antibody heteroconjugates for use in regulation of lymphocyte activity
ES2124533T3 (es) Anticuerpos monoclonales inmunoestimulantes.
ATE387458T1 (de) Fas-antigenbindender ligand
DE3479289D1 (en) Immune response to tumours and viruses induced by anti-idiotype antibodies
IT8019656A0 (it) Polimeri idrocarburici ionici con migliorata adesione al nylon.
ES2176347T3 (es) Modulacion de la respuesta inmune.
NO162797C (no) Monoklonalt antistofff for anvendelse in vitro.
DE3684578D1 (de) Monoklonale antikoerper mit bindungsspezifitaet fuer menschliche prostatatumorantigene und methoden fuer ihre verwendung.
EP0109434A4 (de) In vitro diagnoseverfahren unter verwendung von monoklonalen antikörpern gegen konnektive gewebeproteine.
DE69430846D1 (de) Für natürliche killerzellen spezifische antigene und sie identifizierende antikörper
DE3585049D1 (de) Monoklonale antikoerper.
EP0306680A3 (en) Monoclonal antibodies to anti-thrombin binding substance, and their uses
ATE58397T1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
NO873154L (no) Spesifikke monoklonale antistoffer mot overflatereseptor for ige og hybridcellelinjer som produserer disse antistoffer og anvendelse derav.
Novak T cell repertoire to the synthetic polypeptide antigen poly-18
FR2645967B1 (fr) Procede d'adsorption d'un materiel immunologique, utilisation dans le domaine des reactions antigene/anticorps
ATE99061T1 (de) Monoklonale human-antikoerper, spezifisch fuer rh(d).
ATE16200T1 (de) Monoklonale antikoerper, spezifisch zu menschlichen hematopoietischen zelloberflaechenglycoproteinen.
IE780835L (en) Antibody immobilised in acrylamide copolymer matrix

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee